Should We Use Tegaserod for Irritable Bowel Syndrome?

Conclusions: The uncertainties and lack of reliable evidence regarding tegaserod metabolism and cardiovascular risk estimates may discourage clinical use. Signals for cardiovascular toxicity in typical drug development programs are subtle and must be pursued aggressively, with complete case follow-up and cardiovascular event capture in the clinical trials.
Source: American Journal of Therapeutics - Category: Drugs & Pharmacology Tags: Therapeutic Opinion Source Type: research